Benitec Biopharma Inc.
BNTC
$14.61
-$0.33-2.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -89.71% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -89.71% |
| Cost of Revenue | 100.00% | 97.14% | 98.11% | -- | -1,300.00% |
| Gross Profit | -100.00% | -98.19% | -98.90% | 44.00% | 94.92% |
| SG&A Expenses | 89.56% | 56.65% | 27.12% | 9.51% | -3.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.18% | 10.74% | 9.57% | 17.40% | 11.18% |
| Operating Income | -40.22% | -11.05% | -9.97% | -17.87% | -11.54% |
| Income Before Tax | -22.12% | 1.81% | -2.12% | -11.19% | -8.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.12% | 1.81% | -2.12% | -11.19% | -8.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.12% | 1.81% | -2.12% | -11.19% | -8.63% |
| EBIT | -40.22% | -11.05% | -9.97% | -17.87% | -11.54% |
| EBITDA | -40.40% | -11.10% | -10.13% | -18.25% | -11.81% |
| EPS Basic | 81.14% | 85.32% | 66.79% | 61.23% | 64.31% |
| Normalized Basic EPS | 81.32% | 85.57% | 66.56% | 63.36% | 65.48% |
| EPS Diluted | 81.14% | 85.32% | 66.79% | 61.23% | 64.31% |
| Normalized Diluted EPS | 81.32% | 85.57% | 66.56% | 63.36% | 65.48% |
| Average Basic Shares Outstanding | 225.27% | 646.40% | 471.41% | 474.83% | 462.17% |
| Average Diluted Shares Outstanding | 225.27% | 646.40% | 471.41% | 474.83% | 462.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |